Patients and carers

  • Email
  • Help

Information for you

On this page, you will find information on the Agency’s activities that are most relevant to patients and carers, including news, and events.

You can contribute to the Agency’s work by responding to public consultations.

Learn more about how Patients and carers are actively involved in the work of the Agency.

Featured information

  • Antibiotic awareness initiatives, 13-19 November 2017

    EMA has published a package of information in support of World Antibiotic Awareness Week from 13 to 19 November and European Antibiotic Awareness Day on 18 November. This includes a visual guide to how the EU agencies support the fight against antibiotic resistance and a meeting report and video on its joint info session with the European Centre for Disease Prevention and Control on antimicrobial resistance in September, involving EMA's working parties for patients and consumers and for healthcare professionals. For more information, see Antimicrobial resistance.

  • Ten-year report on implementation of the Paediatric Regulation

    In October 2017, the European Commission published a report on progress made in children's medicines since the Paediatric Regulation came into force 10 years ago. The report shows an increase in medicines for children in many therapeutic areas in the last ten years, most notably in rheumatology and infectious diseases. However, it also shows that little progress has been made in diseases that only affect children or where the disease shows biological differences between adults and children, particularly rare diseases. The Commission and EMA and its Paediatric Committee will develop an action plan to improve the implementation of the Regulation.

  • public_hearing_report

    Public hearing at EMA

    Patients, carers, doctors, pharmacists and academics shared their experiences with valproate, a medicine currently prescribed for epilepsy, bipolar disorder and migraine, at EMA’s public hearing on 26 September 2017. 65 people attended including 28 patients and patient representatives, 19 healthcare professionals and academics, 11 attendees from pharmaceutical industry and 7 from media. There were 25 speaker contributions,grouped into 16 speaker slots. The European Parliament representative concluded that the hearing was a positive experience. A summary report is available.

  • Joint meeting of patients and consumers and healthcare professionals working parties

    EMA held a joint meeting of the Patients' and Consumers' Working Party (PCWP) and the Healthcare Professionals' Working Party (HCPWP) on 20 September. Topics included work plans for 2018-19, proposed revision of their mandates and rules of procedure, streamlining the eligibility status re-assessment processes, compassionate use of medicines, EMA preparedness for Brexit, EMA’s first public hearing and next steps following the European Commission report on product information. All presentations are available.

News for patients and carers

Events of interest

  • 21/11/2017


    Training session for patients, consumers and healthcare professionals interested in European Medicines Agency activities

    This one-day training session for representatives of patients' and consumers' and healthcare professionals’ organisations aims at presenting an overview of medicines evaluation with specific emphasis on where and how they can be involved. Using a hands-on interactive approach, participants will learn more about how they can contribute to scientific advice procedures, Scientific Advisory Group (SAG) meetings and in review of information for patients. ... Read more

  • 22/11/2017


    European Medicines Agency Human Scientific Committees’ Working Party with Patients’ and Consumers’ Organisations (PCWP) meeting with all eligible organisations

    This final meeting for 2017 brings together members of the Patients and Consumers Working Party (PCWP) with all eligible patient and consumer organisations. Topics for discussion include highlights from 2017, feedback on EMA’s first public hearing, some new EMA shareable communications, big data and real world evidence, EMA Action Plan following Commission’s recommendations on product information and EMA’s new EPAR summary template. Other topics for discussion include the PCWP and HCPWP work plans and topic groups for 2018/19, scientific committees’ feedback and Members’ voice. Participants will also be updated on relocation preparedness. ... Read more

  • 14/12/2017 - 15/12/2017


    Workshop on site and histology - Independent indications in oncology

    Biological drivers that define cancer course across anatomical sites and histologies offer an opportunity to select populations sensitive to specific drugs based on those drivers, independently of the specific site or histology. This workshop aims to provide an exchange of views from different stakeholders about situations where a site and histology-independent clinical development might be a viable option and the associated challenges in terms of drug development, benefit-risk evaluation and health-technology assessment. ... Read more

  • 30/11/2017 - 01/12/2017


    Data anonymisation workshop

    The data anonymisation workshop focuses on anonymisation as a key enabler for clinical data sharing. The scope of the workshop includes clinical trial data including individual patient level data and real world data in the context of patient registries and individual cohort studies. ... Read more

  • 19/09/2017


    European Medicines Agency - Payer Community meeting

    The European Medicines Agency and European Union healthcare payers met to explore synergies and foster mutual understanding and cooperation to help improve timely and affordable access for patients to new medicinal products. The meeting aimed to be complementary to EMA's existing cooperation with Health Technology Assessment (HTA) bodies and especially with EUnetHTA. ... Read more

  • See all Events of interest

Information for:

Find information for...

FAQ spotlight